DexCom Price to Free Cash Flow Ratio 2010-2024 | DXCM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

DexCom average price to free cash flow ratio for 2023 was 17.78, a 13.54% decline from 2022.
DexCom average price to free cash flow ratio for 2022 was 15.66, a 94.23% increase from 2021.
DexCom average price to free cash flow ratio for 2021 was 271.53, a 64.26% decline from 2020.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

DexCom average price to free cash flow ratio for 2023 was 17.78, a 13.54% decline from 2022.
DexCom average price to free cash flow ratio for 2022 was 15.66, a 94.23% increase from 2021.
DexCom average price to free cash flow ratio for 2021 was 271.53, a 64.26% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$194.7B
Intuitive Surgical (ISRG)	$191.9B
Alcon (ALC)	$42.1B
Edwards Lifesciences (EW)	$41.4B
IQVIA Holdings (IQV)	$34.7B
IDEXX Laboratories (IDXX)	$34.1B
STERIS (STE)	$20.9B
Waters (WAT)	$20.5B
SONOVA HOLDING (SONVY)	$20.3B
Hologic (HOLX)	$18.2B
Fresenius Medical Care AG KGaA (FMS)	$13B
Sysmex ADR (SSMXY)	$12.7B
Globus Medical (GMED)	$11.3B
Penumbra (PEN)	$9.1B
Teleflex (TFX)	$9B
Masimo (MASI)	$8.8B
Glaukos (GKOS)	$8B
PROCEPT BioRobotics (PRCT)	$4.9B
Integer Holdings (ITGR)	$4.5B
Veracyte (VCYT)	$3B
Inari Medical (NARI)	$3B
LivaNova (LIVN)	$2.8B
TransMedics (TMDX)	$2.8B
Nihon Kohden (NHNKY)	$2.3B
Elekta AB (EKTAY)	$2.2B
Tandem Diabetes Care (TNDM)	$1.8B
RxSight (RXST)	$1.8B
Integra LifeSciences Holdings (IART)	$1.8B
Alphatec Holdings (ATEC)	$1.4B
Artivion (AORT)	$1.1B